Judit Börcsök

Sep 18, 2024 | nature.com | Miklos Diossy |Pranshu Sahgal |Judit Börcsök |Dávid Szüts |Alan D. D’Andrea |István Csabai | +2 more

AbstractWe analyzed genomic data from the prostate cancer of African- and European American men to identify differences contributing to racial disparity of outcome. We also performed FISH-based studies of Chromodomain helicase DNA-binding protein 1 (CHD1) loss on prostate cancer tissue microarrays. We created CHD1-deficient prostate cancer cell lines for genomic, drug sensitivity and functional homologous recombination (HR) activity analysis.

Apr 7, 2024 | nature.com | Pranshu Sahgal |Brandon Huffman |Judit Börcsök |István Csabai |Michael Cecchini

AbstractHomologous recombination (HR) and nucleotide excision repair (NER) are the two most frequently disabled DNA repair pathways in cancer. HR-deficient breast, ovarian, pancreatic and prostate cancers respond well to platinum chemotherapy and PARP inhibitors. However, the frequency of HR deficiency in gastric and esophageal adenocarcinoma (GEA) still lacks diagnostic and functional validation.

Nov 22, 2023 | science.org | Yuzhen Zhou |Mikito Shimizu |Paloma Bravo |Judit Börcsök

ATM deficiency confers specific therapeutic vulnerabilities in bladder cancerYuzhen Zhou https://orcid.org/0000-0003-0461-2963, Judit Börcsök https://orcid.org/0000-0002-3290-3971, [...] , Elio Adib https://orcid.org/0000-0003-0594-7976, Sophia C. Kamran https://orcid.org/0000-0001-9283-6515, [...] , Alexander J.